Clinical researchers reported encouraging Phase II trial results combining a radiopharmaceutical agent with stereotactic body radiation therapy (SBRT) for oligometastatic recurrent prostate cancer. The LUNAR study demonstrated extended progression-free survival compared to SBRT alone, indicating enhanced disease control potential. UCLA’s Jonsson Comprehensive Cancer Center data underscores PSMA-targeted radioligand therapy's integration into prostate cancer treatment. Additionally, a genomic test predicts hormone therapy benefits post-prostatectomy, advancing personalized treatment strategies.